Yes, Entresto Must Be Discontinued Immediately If Facial Edema Develops
If facial edema occurs in a patient taking Entresto (sacubitril/valsartan), the medication must be discontinued immediately, regardless of how long the patient has been on it. 1
Critical Safety Directive from FDA Labeling
The FDA label for Entresto is unequivocal: "If angioedema occurs, discontinue ENTRESTO immediately, provide appropriate therapy, and monitor for airway compromise. ENTRESTO must not be re-administered." 1 This is a black-and-white directive with no exceptions for duration of therapy.
Why Duration of Therapy Doesn't Matter
A critical misconception is that angioedema only occurs early in treatment. While ACE inhibitor-associated angioedema most frequently occurs within the first month, it can occur even after many years of continuous therapy 2. The same principle applies to Entresto, which contains valsartan (an ARB component) and sacubitril (a neprilysin inhibitor), both of which can trigger angioedema through bradykinin-mediated mechanisms.
Immediate Management Steps
- Discontinue Entresto immediately - do not wait to see if symptoms resolve
- Assess airway involvement - examine tongue, glottis, and larynx for swelling
- If laryngeal involvement: Administer subcutaneous epinephrine 1:1000 (0.3-0.5 mL) and ensure airway patency 1
- Monitor closely - angioedema with laryngeal edema can be fatal 1
- Consider antihistamines for symptomatic relief of facial/lip swelling 2
Important Clinical Nuances
- Facial edema alone may resolve without treatment if confined to face and lips, but the drug must still be stopped 1
- Standard treatments often fail: Epinephrine, antihistamines, and corticosteroids do not reliably work for bradykinin-mediated angioedema 2
- Swelling can persist: The tendency to swell may continue for at least 6 weeks after discontinuation 2
- Higher risk populations: Black patients have significantly higher rates of angioedema with Entresto 1, 3
Do Not Rechallenge
Entresto must never be restarted in a patient who has experienced angioedema 1. This is an absolute contraindication. Recent data show that patients who switch from ACE inhibitors or ARBs to Entresto within 14 days have increased angioedema risk (HR 1.98-2.45) 4, but once angioedema occurs on Entresto itself, rechallenge is prohibited.
Alternative Management
After discontinuation, consider:
- Standard ACE inhibitors or ARBs may be options if the patient has not previously had angioedema with these agents
- However, if C1 esterase inhibitor deficiency is diagnosed, ACE inhibitors are contraindicated 2
- Evaluate for hereditary angioedema if recurrent episodes occur 2
Common Pitfall to Avoid
Do not assume facial edema is "just fluid overload" in a heart failure patient. Angioedema is non-dependent, asymmetric, non-pruritic swelling that differs from volume overload edema. When in doubt, stop the drug - the mortality risk from laryngeal angioedema outweighs any benefit from continuing Entresto.